Year None202120202019201820172016 Date Latest Press Release May 6, 2021 Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update May 3, 2021 Eiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to Multi-Center Phase 3 TOGETHER COVID-19 Study in Brazil April 29, 2021 Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thursday, May 6, 2021 April 22, 2021 Eiger BioPharmaceuticals Appoints Commercial Expert and Industry Veteran Kim Sablich to its Board of Directors March 9, 2021 Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update February 23, 2021 Eiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & Metabolism February 8, 2021 Eiger Announces ILIAD Study Results of Peginterferon Lambda in COVID-19 Published in Lancet Respiratory Medicine 2021 January 25, 2021 Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy™ (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies January 7, 2021 Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans November 23, 2020 Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
